1.19
price down icon0.83%   -0.01
after-market After Hours: 1.20 0.01 +0.84%
loading
Immunic Inc stock is traded at $1.19, with a volume of 852.59K. It is down -0.83% in the last 24 hours and down -26.09% over the past month. Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$1.20
Open:
$1.23
24h Volume:
852.59K
Relative Volume:
1.34
Market Cap:
$108.09M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.3469
EPS:
-3.43
Net Cash Flow:
$-71.16M
1W Performance:
-9.16%
1M Performance:
-26.09%
6M Performance:
-13.14%
1Y Performance:
+5.31%
1-Day Range:
Value
$1.19
$1.255
1-Week Range:
Value
$1.15
$1.33
52-Week Range:
Value
$0.9451
$2.11

Immunic Inc Stock (IMUX) Company Profile

Name
Name
Immunic Inc
Name
Phone
(332) 255-9818
Name
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Name
Employee
85
Name
Twitter
@ImmunicInc
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IMUX's Discussions on Twitter

Immunic Inc Stock (IMUX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-21-22 Downgrade SVB Leerink Outperform → Mkt Perform
Sep-19-22 Resumed H.C. Wainwright Buy
Apr-15-21 Initiated Aegis Capital Buy
Mar-24-21 Initiated JMP Securities Mkt Outperform
Oct-02-20 Initiated SVB Leerink Outperform
Aug-26-20 Initiated Piper Sandler Overweight
Aug-07-20 Resumed ROTH Capital Buy
Jul-20-20 Initiated BMO Capital Markets Outperform
Jun-05-20 Initiated Wedbush Outperform
May-11-20 Initiated H.C. Wainwright Buy
Mar-25-20 Initiated ROTH Capital Buy
Jul-11-19 Initiated Chardan Capital Markets Buy
View All

Immunic Inc Stock (IMUX) Latest News

pulisher
08:59 AM

Immunic's Jessica Breu talks BIO-Europe & MS research advancements - Proactive Investors USA

08:59 AM
pulisher
02:29 AM

Vanguard Group's Strategic Acquisition of Immunic Inc Shares - GuruFocus.com

02:29 AM
pulisher
Nov 04, 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - Quantisnow

Nov 04, 2024
pulisher
Nov 01, 2024

Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 29, 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November - StockTitan

Oct 29, 2024
pulisher
Oct 29, 2024

Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20 - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - Simply Wall St

Oct 25, 2024
pulisher
Oct 23, 2024

Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials - Proactive Investors Australia

Oct 23, 2024
pulisher
Oct 23, 2024

Immunic late-stage program for lead asset to proceed as planned - MSN

Oct 23, 2024
pulisher
Oct 22, 2024

Data monitoring committee OKs continuation of phase 3 trial for vidofludimus calcium - Healio

Oct 22, 2024
pulisher
Oct 22, 2024

Interim analysis allows Immunic to stick with phase III MS studies - BioWorld Online

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic stock slips after trial update (IMUX:NASDAQ) - Seeking Alpha

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic Phase 3 MS study advances following positive recommendation from independent committee - Proactive financial news

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic Shares Up 12% on Positive MS Drug Analysis - MarketWatch

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic's phase 3 ENSURE trials for MS drug proceed as planned - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - Marketscreener.com

Oct 22, 2024
pulisher
Oct 22, 2024

EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosisboerse.de - boerse.de

Oct 22, 2024
pulisher
Oct 21, 2024

Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq

Oct 21, 2024
pulisher
Oct 18, 2024

FY2024 EPS Estimates for Immunic Lowered by Analyst - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Research Analysts Offer Predictions for Immunic Q4 Earnings - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully - Yahoo Canada Finance

Oct 16, 2024
pulisher
Oct 16, 2024

Focus on long-term protection - European Biotechnology News

Oct 16, 2024
pulisher
Oct 14, 2024

Stock Surge: Immunic Inc (IMUX) Closes at 1.40, Marking a 0.00 Increase/Decrease - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Investing in Immunic Inc (IMUX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Has $44,000 Stock Holdings in Immunic, Inc. (NASDAQ:IMUX) - Defense World

Oct 14, 2024
pulisher
Oct 12, 2024

Renaissance Technologies LLC Has $323,000 Stake in Immunic, Inc. (NASDAQ:IMUX) - MarketBeat

Oct 12, 2024
pulisher
Oct 09, 2024

Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ... - Yahoo Finance UK

Oct 09, 2024
pulisher
Oct 04, 2024

Future of oral small molecule drugs – addressing potential in multiple sclerosis - European Pharmaceutical Review

Oct 04, 2024
pulisher
Oct 04, 2024

Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts - MarketBeat

Oct 04, 2024
pulisher
Sep 27, 2024

Immunic CMO on key ECTRIMS highlights and MS research - Proactive Investors USA

Sep 27, 2024
pulisher
Sep 25, 2024

Get in on Immunic Inc’s (IMUX) buy-in window today! - SETE News

Sep 25, 2024
pulisher
Sep 24, 2024

IMUX’s 2023 Market Saga: Unraveling the Story of Gains and Losses - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Market Momentum Report: Immunic Inc (IMUX)’s Negative Close at 1.60 - The Dwinnex

Sep 24, 2024
pulisher
Sep 23, 2024

Analysts review Immunome Inc’s rating - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

IMAX (NYSE:IMAX) Stock Price Down 4.9% - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Ratio Review: Analyzing Imunon Inc (IMNN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

IMAX Co. (NYSE:IMAX) Shares Sold by Rhumbline Advisers - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

What is the investor’s view on Immunic Inc (IMUX)? - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Immuneering Corp Inc. (IMRX) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Hancock Whitney Corp Sells 2,958 Shares of Polaris Inc. (NYSE:PII) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

You might want to take a look at Inuvo Inc (INUV) now - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Imunon Inc (IMNN) may enjoy gains as insiders got busy in the recent days - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Applied Fundamental Research LLC Decreases Stock Holdings in UFP Technologies, Inc. (NASDAQ:UFPT) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

UniQure rises on orphan drug status for genetic disorder gene therapy - XM

Sep 23, 2024
pulisher
Sep 23, 2024

uniQure Gains FDA Orphan Drug Status for Fabry Disease Therapy - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

UFP Industries, Inc. (NASDAQ:UFPI) Holdings Decreased by Seven Eight Capital LP - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Unichem Laboratories Set To Discuss US Business Consolidation At Upcoming Board Meeting - NDTV Profit

Sep 23, 2024

Immunic Inc Stock (IMUX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):